CovidStanfordV1, Main, Exploration, bibRecord, 000809

Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Identifieur interne : 000809 ( Main/Exploration ); précédent : 000808; suivant : 000810

Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Auteurs : Fabian Sanchis-Gomar [Espagne, États-Unis] ; Carl J. Lavie [États-Unis] ; Daniel P. Morin [États-Unis] ; Carme Perez-Quilis [Espagne] ; Jari A. Laukkanen [Finlande] ; Marco V. Perez [États-Unis]

Source :

American journal of cardiovascular drugs : drugs, devices, and other interventions [ 1179-187X ] ; 2020.

RBID : pubmed:32737841

Descripteurs français

KwdFr :
- Amiodarone (pharmacologie), Antiarythmiques (pharmacologie), Antiviraux (pharmacologie), Appréciation des risques (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (physiologie), Humains (MeSH), Infections à coronavirus (métabolisme), Infections à coronavirus (physiopathologie), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (traitement médicamenteux), Pandémies (prévention et contrôle), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (métabolisme), Pneumopathie virale (physiopathologie), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (traitement médicamenteux), Pénétration virale (effets des médicaments et des substances chimiques), Résultat thérapeutique (MeSH), Troubles du rythme cardiaque (traitement médicamenteux), Troubles du rythme cardiaque (virologie).
MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus, Pénétration virale.
- métabolisme : Infections à coronavirus, Peptidyl-Dipeptidase A, Pneumopathie virale.
- pharmacologie : Amiodarone, Antiarythmiques, Antiviraux.
- physiologie : Betacoronavirus.
- physiopathologie : Infections à coronavirus, Pneumopathie virale.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale, Troubles du rythme cardiaque.
- virologie : Troubles du rythme cardiaque.
- Appréciation des risques, Humains, Résultat thérapeutique.

English descriptors

KwdEn :
- Amiodarone (pharmacology), Angiotensin-Converting Enzyme 2 (MeSH), Anti-Arrhythmia Agents (pharmacology), Antiviral Agents (pharmacology), Arrhythmias, Cardiac (drug therapy), Arrhythmias, Cardiac (virology), Betacoronavirus (drug effects), Betacoronavirus (physiology), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (metabolism), Coronavirus Infections (physiopathology), Coronavirus Infections (prevention & control), Humans (MeSH), Pandemics (prevention & control), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (drug therapy), Pneumonia, Viral (metabolism), Pneumonia, Viral (physiopathology), Pneumonia, Viral (prevention & control), Risk Assessment (MeSH), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH), Virus Internalization (drug effects).
MESH :
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Amiodarone, Anti-Arrhythmia Agents, Antiviral Agents.
- chemical : Angiotensin-Converting Enzyme 2.
- drug effects : Betacoronavirus, Virus Internalization.
- drug therapy : Arrhythmias, Cardiac, Coronavirus Infections, Pneumonia, Viral.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- virology : Arrhythmias, Cardiac.
- COVID-19, Humans, Risk Assessment, SARS-CoV-2, Treatment Outcome.

Abstract

Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.

DOI: 10.1007/s40256-020-00429-7
PubMed: 32737841
PubMed Central: PMC7394926

Affiliations:

Espagne, Finlande, États-Unis
Californie, Louisiane

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000455
to stream Main, to step Curation: 000455

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?</title>
<author><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain. fabian.sanchis@uv.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. fabian.sanchis@uv.es.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lavie, Carl J" sort="Lavie, Carl J" uniqKey="Lavie C" first="Carl J" last="Lavie">Carl J. Lavie</name>
<affiliation wicri:level="2"><nlm:affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morin, Daniel P" sort="Morin, Daniel P" uniqKey="Morin D" first="Daniel P" last="Morin">Daniel P. Morin</name>
<affiliation wicri:level="2"><nlm:affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perez Quilis, Carme" sort="Perez Quilis, Carme" uniqKey="Perez Quilis C" first="Carme" last="Perez-Quilis">Carme Perez-Quilis</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Laukkanen, Jari A" sort="Laukkanen, Jari A" uniqKey="Laukkanen J" first="Jari A" last="Laukkanen">Jari A. Laukkanen</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio, Finland.</nlm:affiliation>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio</wicri:regionArea>
<wicri:noRegion>Kuopio</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Central Finland Health Care District, Jyvaskyla, Finland.</nlm:affiliation>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Medicine, Central Finland Health Care District, Jyvaskyla</wicri:regionArea>
<wicri:noRegion>Jyvaskyla</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Perez, Marco V" sort="Perez, Marco V" uniqKey="Perez M" first="Marco V" last="Perez">Marco V. Perez</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32737841</idno>
<idno type="pmid">32737841</idno>
<idno type="doi">10.1007/s40256-020-00429-7</idno>
<idno type="pmc">PMC7394926</idno>
<idno type="wicri:Area/Main/Corpus">000455</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000455</idno>
<idno type="wicri:Area/Main/Curation">000455</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000455</idno>
<idno type="wicri:Area/Main/Exploration">000455</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?</title>
<author><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain. fabian.sanchis@uv.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. fabian.sanchis@uv.es.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lavie, Carl J" sort="Lavie, Carl J" uniqKey="Lavie C" first="Carl J" last="Lavie">Carl J. Lavie</name>
<affiliation wicri:level="2"><nlm:affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morin, Daniel P" sort="Morin, Daniel P" uniqKey="Morin D" first="Daniel P" last="Morin">Daniel P. Morin</name>
<affiliation wicri:level="2"><nlm:affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perez Quilis, Carme" sort="Perez Quilis, Carme" uniqKey="Perez Quilis C" first="Carme" last="Perez-Quilis">Carme Perez-Quilis</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Laukkanen, Jari A" sort="Laukkanen, Jari A" uniqKey="Laukkanen J" first="Jari A" last="Laukkanen">Jari A. Laukkanen</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio, Finland.</nlm:affiliation>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio</wicri:regionArea>
<wicri:noRegion>Kuopio</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Central Finland Health Care District, Jyvaskyla, Finland.</nlm:affiliation>
<country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Medicine, Central Finland Health Care District, Jyvaskyla</wicri:regionArea>
<wicri:noRegion>Jyvaskyla</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Perez, Marco V" sort="Perez, Marco V" uniqKey="Perez M" first="Marco V" last="Perez">Marco V. Perez</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">American journal of cardiovascular drugs : drugs, devices, and other interventions</title>
<idno type="eISSN">1179-187X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amiodarone (pharmacology)</term>
<term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Anti-Arrhythmia Agents (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Arrhythmias, Cardiac (drug therapy)</term>
<term>Arrhythmias, Cardiac (virology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (physiology)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (prevention & control)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (metabolism)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Risk Assessment (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Virus Internalization (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amiodarone (pharmacologie)</term>
<term>Antiarythmiques (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (métabolisme)</term>
<term>Infections à coronavirus (physiopathologie)</term>
<term>Infections à coronavirus (prévention et contrôle)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (prévention et contrôle)</term>
<term>Peptidyl-Dipeptidase A (métabolisme)</term>
<term>Pneumopathie virale (métabolisme)</term>
<term>Pneumopathie virale (physiopathologie)</term>
<term>Pneumopathie virale (prévention et contrôle)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pénétration virale (effets des médicaments et des substances chimiques)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Troubles du rythme cardiaque (traitement médicamenteux)</term>
<term>Troubles du rythme cardiaque (virologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amiodarone</term>
<term>Anti-Arrhythmia Agents</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiotensin-Converting Enzyme 2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arrhythmias, Cardiac</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Pénétration virale</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amiodarone</term>
<term>Antiarythmiques</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pandémies</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Troubles du rythme cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Troubles du rythme cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Arrhythmias, Cardiac</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Risk Assessment</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term>
<term>Humains</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32737841</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-187X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>20</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>American journal of cardiovascular drugs : drugs, devices, and other interventions</Title>
<ISOAbbreviation>Am J Cardiovasc Drugs</ISOAbbreviation>
</Journal>
<ArticleTitle>Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?</ArticleTitle>
<Pagination><MedlinePgn>413-418</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s40256-020-00429-7</ELocationID>
<Abstract><AbstractText>Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchis-Gomar</LastName>
<ForeName>Fabian</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-0424-4208</Identifier>
<AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain. fabian.sanchis@uv.es.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. fabian.sanchis@uv.es.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lavie</LastName>
<ForeName>Carl J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morin</LastName>
<ForeName>Daniel P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perez-Quilis</LastName>
<ForeName>Carme</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laukkanen</LastName>
<ForeName>Jari A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medicine, Central Finland Health Care District, Jyvaskyla, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perez</LastName>
<ForeName>Marco V</ForeName>
<Initials>MV</Initials>
<AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Am J Cardiovasc Drugs</MedlineTA>
<NlmUniqueID>100967755</NlmUniqueID>
<ISSNLinking>1175-3277</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N3RQ532IUT</RegistryNumber>
<NameOfSubstance UI="D000638">Amiodarone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000638" MajorTopicYN="N">Amiodarone</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001145" MajorTopicYN="Y">Arrhythmias, Cardiac</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32737841</ArticleId>
<ArticleId IdType="doi">10.1007/s40256-020-00429-7</ArticleId>
<ArticleId IdType="pii">10.1007/s40256-020-00429-7</ArticleId>
<ArticleId IdType="pmc">PMC7394926</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Int J Infect Dis. 2020 Apr;93:268-276</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32081774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Jun 23;64(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32366720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 2013 Jul;386(7):571-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23568552</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2012 Oct;27(5):447-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22226422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 1997 Sep 2;96(5):1386-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9315521</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2008 Aug;39(2):142-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18314540</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Prev Cardiol. 2020 Apr 16;:2047487320919233</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32295404</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Cardiovasc Drugs. 2020 Dec;20(6):549-558</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32166725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2007 Jul 2;566(1-3):215-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17475238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008719</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ J. 2009 Apr;73(4):622-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19318723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2016 Jan;71(1):280-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26429565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Biol Sci. 2020 Mar 15;16(10):1724-1731</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32226290</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ J. 2009 Apr;73(4):639-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19225199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thromb Haemost. 2012 Mar;107(3):597-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22318427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Cardiovasc Med. 2020 May 05;7:85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32432127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 1999 Aug 17;100(7):690-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10449688</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pathog Dis. 2015 Jul;73(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25933611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2006 Dec 20;296(23):2839-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17179461</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Cardiol. 1999 Feb 1;83(3):388-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10072229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Transl Med. 2020 Jun;8(11):693</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32617313</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2020 Sep;158(3):1069-1078</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32333929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 2013 Jul;386(7):635-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23579385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine. 2002 Feb 21;17(4):197-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11991672</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
<li>Finlande</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Louisiane</li>
</region>
</list>
<tree><country name="Espagne"><noRegion><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
</noRegion>
<name sortKey="Perez Quilis, Carme" sort="Perez Quilis, Carme" uniqKey="Perez Quilis C" first="Carme" last="Perez-Quilis">Carme Perez-Quilis</name>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
</region>
<name sortKey="Lavie, Carl J" sort="Lavie, Carl J" uniqKey="Lavie C" first="Carl J" last="Lavie">Carl J. Lavie</name>
<name sortKey="Morin, Daniel P" sort="Morin, Daniel P" uniqKey="Morin D" first="Daniel P" last="Morin">Daniel P. Morin</name>
<name sortKey="Perez, Marco V" sort="Perez, Marco V" uniqKey="Perez M" first="Marco V" last="Perez">Marco V. Perez</name>
</country>
<country name="Finlande"><noRegion><name sortKey="Laukkanen, Jari A" sort="Laukkanen, Jari A" uniqKey="Laukkanen J" first="Jari A" last="Laukkanen">Jari A. Laukkanen</name>
</noRegion>
<name sortKey="Laukkanen, Jari A" sort="Laukkanen, Jari A" uniqKey="Laukkanen J" first="Jari A" last="Laukkanen">Jari A. Laukkanen</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000809 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000809 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32737841
   |texte=   Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32737841" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki